{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:49:39Z","timestamp":1778568579195,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,11]],"date-time":"2027-02-11T00:00:00Z","timestamp":1802304000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005302","name":"Alexander S. Onassis Public Benefit Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI082714"],"award-info":[{"award-number":["AI082714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR053483"],"award-info":[{"award-number":["AR053483"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DE028001"],"award-info":[{"award-number":["DE028001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR060804"],"award-info":[{"award-number":["AR060804"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM104938"],"award-info":[{"award-number":["GM104938"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jim.2026.114038","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:54:14Z","timestamp":1770134054000},"page":"114038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Muscarinic 3 receptor antibodies in Sj\u00f6gren's disease: Evaluating assay variability and detection methods"],"prefix":"10.1016","volume":"547","author":[{"given":"Martha","family":"Tsaliki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devavrat","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biji T.","family":"Kurien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Hal","family":"Scofield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0005","first-page":"151","article-title":"Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Bacman","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0010","first-page":"321","article-title":"Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sj\u00f6gren syndrome","volume":"42","author":"Bacman","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.jim.2026.114038_bb0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren\u2019s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jim.2026.114038_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jim.2015.11.005","article-title":"A novel cell-based assay for inhibitory anti-muscarinic type 3 receptor antibodies in primary Sjogren\u2019s syndrome","volume":"427","author":"Bastian","year":"2015","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/clim.2002.5228","article-title":"Role of salivary IgA in the pathogenesis of Sjogren syndrome","volume":"104","author":"Berra","year":"2002","journal-title":"Clin. Immunol."},{"issue":"4814","key":"10.1016\/j.jim.2026.114038_bb0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.3037705","article-title":"Identification of a family of muscarinic acetylcholine receptor genes","volume":"237","author":"Bonner","year":"1987","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/1744666X.2016.1109449","article-title":"Early diagnosis of primary Sj\u00f6gren\u2019s syndrome: EULAR-SS task force clinical recommendations","volume":"12","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jim.2026.114038_bb0040","series-title":"Sjogren Syndrome","author":"Carsons","year":"2025"},{"issue":"6","key":"10.1016\/j.jim.2026.114038_bb0045","first-page":"1342","article-title":"Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sj\u00f6gren\u2019s syndrome","volume":"29","author":"Cavill","year":"2002","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.jim.2026.114038_bb0050","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1002\/art.11343","article-title":"Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission","volume":"48","author":"Cavill","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jim.2026.114038_bb0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.0300-9475.2004.01395.x","article-title":"Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren\u2019s syndrome","volume":"59","author":"Cavill","year":"2004","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.jim.2026.114038_bb0060","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.10258","article-title":"Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sj\u00f6gren\u2019s syndrome) on a healthy murine background","volume":"46","author":"Cha","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0065","first-page":"296","article-title":"Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren\u2019s syndrome-associated autoantibodies","volume":"33","author":"Cha","year":"2006","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.jim.2026.114038_bb0070","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/rheumatology\/keh389","article-title":"Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren\u2019s syndrome using conventional immunological approaches","volume":"43","author":"Dawson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.jim.2026.114038_bb0075","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/art.21347","article-title":"Antimuscarinic antibodies in Sjogren\u2019s syndrome: where are we, and where are we going?","volume":"52","author":"Dawson","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0080","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.21764","article-title":"Antimuscarinic antibodies in primary Sj\u00f6gren\u2019s syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells","volume":"54","author":"Dawson","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000345177","article-title":"Neuroimmune interactions in Sjogren's syndrome: relationship of exocrine gland dysfunction with autoantibodies to muscarinic acetylcholine receptor-3 and mental health status parameters","volume":"20","author":"Deak","year":"2013","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116744","article-title":"Meta-analysis of anti-muscarinic receptor type 3 antibodies for the diagnosis of Sjogren syndrome","volume":"10","author":"Deng","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41927-023-00368-1","article-title":"The study of serum muscarinic acetylcholine receptor subtype 3 (m3AChR)-specific autoantibodies level in rheumatoid arthritis patients with secondary sjogren syndrome","volume":"7","author":"Fakher","year":"2023","journal-title":"BMC Rheumatol."},{"issue":"3","key":"10.1016\/j.jim.2026.114038_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren\u2019s Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"8","key":"10.1016\/j.jim.2026.114038_bb0105","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1002\/art.20371","article-title":"Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren\u2019s syndrome patients by use of a transfected cell line assay","volume":"50","author":"Gao","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1985.tb01088.x","article-title":"The assay for thyroid stimulating immunoglobulins using cultured human thyroid cells","volume":"23","author":"Grant","year":"1985","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"6","key":"10.1016\/j.jim.2026.114038_bb0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2183\/pjab.89.226","article-title":"Molecular properties of muscarinic acetylcholine receptors","volume":"89","author":"Haga","year":"2013","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"5","key":"10.1016\/j.jim.2026.114038_bb0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/rheumatology\/keq420","article-title":"Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren\u2019s syndrome","volume":"50","author":"He","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jim.2026.114038_bb0125","first-page":"322","article-title":"The role of muscarinic acetylcholine receptor type 3 polypeptide (M3RP205-220) antibody in the saliva of patients with primary Sjogren\u2019s syndrome","volume":"30","author":"He","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaut.2010.08.004","article-title":"Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjogren\u2019s syndrome-like sialoadenitis","volume":"35","author":"Iizuka","year":"2010","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.jim.2026.114038_bb0135","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1006\/bbrc.1998.8395","article-title":"Acetylcholine acts on M3 muscarinic receptors and induces the translocation of aquaporin5 water channel via cytosolic Ca2+ elevation in rat parotid glands","volume":"245","author":"Ishikawa","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.jim.2026.114038_bb0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10067-016-3186-0","article-title":"Younger patients with primary Sjogren\u2019s syndrome are more likely to have salivary IgG anti-muscarinic acetylcholine receptor type 3 antibodies","volume":"35","author":"Jayakanthan","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbadis.2011.11.012","article-title":"Autoantibodies in primary Sjogren\u2019s syndrome patients induce internalization of muscarinic type 3 receptors","volume":"1822","author":"Jin","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbadis.2011.11.012","article-title":"Autoantibodies in primary Sj\u00f6gren's syndrome patients induce internalization of muscarinic type 3 receptors","volume":"1822","author":"Jin","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"17","key":"10.1016\/j.jim.2026.114038_bb0155","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2013.278448","article-title":"Autoantibodies present before symptom onset in primary Sjogren syndrome","volume":"310","author":"Jonsson","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jim.2026.114038_bb0160","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0022034515577813","article-title":"Effect of antimuscarinic autoantibodies in primary Sjogren\u2019s syndrome","volume":"94","author":"Kim","year":"2015","journal-title":"J. Dent. Res."},{"issue":"6","key":"10.1016\/j.jim.2026.114038_bb0165","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/rheumatology\/ken064","article-title":"Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjogren\u2019s syndrome patients","volume":"47","author":"Koo","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.jim.2026.114038_bb0170","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/rheumatology\/keh672","article-title":"Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren\u2019s syndrome","volume":"44","author":"Kov\u00e1cs","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jim.2026.114038_bb0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.clim.2008.04.001","article-title":"Demonstration of autoantibody binding to muscarinic acetylcholine receptors in the salivary gland in primary Sjogren\u2019s syndrome","volume":"128","author":"Kovacs","year":"2008","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jim.2026.114038_bb0180","first-page":"886","article-title":"Induction of anti-Ro60\/anti-La by immunisation with spectrin and induction of anti-spectrin by immunisation with Ro60 and 4-hydroxy-2-nonenal-modified Ro60 immunisation","volume":"30","author":"Kurien","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae114","article-title":"Experimental induction of anti-muscarinic type-3-receptor extracellular loop antibodies by immunization with 4-hydroxy-2-nonenal modified Ro60 and unmodified Ro60","volume":"219","author":"Kurien","year":"2025","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jim.2026.114038_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2013.11.001","article-title":"A comprehensive review of autoantibodies in primary Sjogren\u2019s syndrome: clinical phenotypes and regulatory mechanisms","volume":"51","author":"Kyriakidis","year":"2014","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053113","article-title":"Autoantibodies against muscarinic type 3 receptor in Sjogren\u2019s syndrome inhibit aquaporin 5 trafficking","volume":"8","author":"Lee","year":"2013","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.jim.2026.114038_bb0200","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/labinvest.3700173","article-title":"Inhibitory effects of autoantibodies on the muscarinic receptors in Sj\u00f6gren\u2019s syndrome","volume":"84","author":"Li","year":"2004","journal-title":"Lab. Invest."},{"issue":"16","key":"10.1016\/j.jim.2026.114038_bb0205","first-page":"2490","article-title":"Serum IgA against type 3 muscarinic acetylcholine receptor is a novel marker in diagnosis of Sjogren\u2019s syndrome","volume":"124","author":"Li","year":"2011","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"10.1016\/j.jim.2026.114038_bb0210","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1002\/art.38872","article-title":"Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjogren\u2019s syndrome","volume":"66","author":"Maier-Moore","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"17","key":"10.1016\/j.jim.2026.114038_bb0215","doi-asserted-by":"crossref","first-page":"9579","DOI":"10.1073\/pnas.97.17.9579","article-title":"Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype","volume":"97","author":"Matsui","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0220","doi-asserted-by":"crossref","first-page":"795","DOI":"10.55563\/clinexprheumatol\/gy6udz","article-title":"Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Mona","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0225","doi-asserted-by":"crossref","first-page":"795","DOI":"10.55563\/clinexprheumatol\/gy6udz","article-title":"Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjogren\u2019s syndrome","volume":"39","author":"Mona","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.jim.2026.114038_bb0230","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2004.025478","article-title":"Muscarinic acetylcholine receptor autoantibodies in patients with Sjogren\u2019s syndrome","volume":"64","author":"Naito","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0235","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2007.072421","article-title":"High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sj\u00f6gren syndrome","volume":"67","author":"Nakamura","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jim.2026.114038_bb0240","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.30282","article-title":"Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren\u2019s syndrome","volume":"63","author":"Park","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0245","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molimm.2013.06.004","article-title":"The inhibitory effects of antimuscarinic autoantibodies in the sera of primary Sjogren syndrome patients on the gastrointestinal motility","volume":"56","author":"Park","year":"2013","journal-title":"Mol. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jim.2026.114038_bb0250","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2004.01.019","article-title":"Autoantibodies against cerebral muscarinic cholinoceptors in Sjogren syndrome: functional and pathological implications","volume":"150","author":"Reina","year":"2004","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.jim.2026.114038_bb0255","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1177\/154405910708600905","article-title":"Cholinoreceptor autoantibodies in Sjogren syndrome","volume":"86","author":"Reina","year":"2007","journal-title":"J. Dent. Res."},{"issue":"5","key":"10.1016\/j.jim.2026.114038_bb0260","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.archoralbio.2010.08.017","article-title":"Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjogren\u2019s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands","volume":"56","author":"Reina","year":"2011","journal-title":"Arch. Oral Biol."},{"issue":"1\u20132","key":"10.1016\/j.jim.2026.114038_bb0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cellimm.2012.03.006","article-title":"Anti-M(3) peptide IgG from Sjogren\u2019s syndrome triggers apoptosis in A253 cells","volume":"275","author":"Reina","year":"2012","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard.2010.129049","article-title":"Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjogren\u2019s syndrome","volume":"70","author":"Roescher","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1573397112666160714164149","article-title":"Update on pathogenesis of Sjogren\u2019s syndrome","volume":"13","author":"Sandhya","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"issue":"10","key":"10.1016\/j.jim.2026.114038_bb0280","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1074\/jbc.M610394200","article-title":"Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation","volume":"282","author":"Scarselli","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jim.2026.114038_bb0285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biologicals.2007.11.001","article-title":"Evidence that anti-muscarinic antibodies in Sjogren\u2019s syndrome recognise both M3R and M1R","volume":"36","author":"Schegg","year":"2008","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League against rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3343\/alm.2019.39.1.3","article-title":"Laboratory testing in thyroid conditions - pitfalls and clinical utility","volume":"39","author":"Soh","year":"2019","journal-title":"Ann. Lab. Med."},{"issue":"10","key":"10.1016\/j.jim.2026.114038_bb0300","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-024-01007-1","article-title":"A golden age of muscarinic acetylcholine receptor modulation in neurological diseases","volume":"23","author":"Tobin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jim.2026.114038_bb0305","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2249.2010.04188.x","article-title":"New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjogren\u2019s syndrome","volume":"162","author":"Tsuboi","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jim.2026.114038_bb0310","doi-asserted-by":"crossref","first-page":"1003054","DOI":"10.3389\/fimmu.2022.1003054","article-title":"Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren\u2019s syndrome: a critical review","volume":"13","author":"Vilchez-Oya","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jim.2026.114038_bb0315","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jim.2026.114038_bb0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2019.04.009","article-title":"Sjogren\u2019s syndrome: an update on disease pathogenesis, clinical manifestations and treatment","volume":"203","author":"Vivino","year":"2019","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.jim.2026.114038_bb0325","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1002\/art.20625","article-title":"Passive transfer of Sjogren\u2019s syndrome IgG produces the pathophysiology of overactive bladder","volume":"50","author":"Wang","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jim.2026.114038_bb0330","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P","article-title":"Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren\u2019s syndrome","volume":"43","author":"Waterman","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jim.2026.114038_bb0335","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/485213","article-title":"Effects of muscarinic acetylcholine 3 receptor(208-227) peptide immunization on autoimmune response in nonobese diabetic mice","volume":"2013","author":"Yang","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.jim.2026.114038_bb0340","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.jim.2026.114038_bb0345","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jim.2016.07.003","article-title":"Muscarinic type 3 receptor autoantibodies are associated with anti-SSA\/Ro autoantibodies in Sjogren\u2019s syndrome","volume":"437","author":"Zuo","year":"2016","journal-title":"J. Immunol. Methods"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:59:51Z","timestamp":1777417191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175926000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":69,"alternative-id":["S0022175926000141"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2026.114038","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Muscarinic 3 receptor antibodies in Sj\u00f6gren's disease: Evaluating assay variability and detection methods","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2026.114038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114038"}}